CDT Equity (CDT) Non-Current Debt (2023 - 2024)

CDT Equity's (CDT) quarterly Non-Current Debt came in at $200000.0 in Q3 2024, little changed on a QoQ basis from $200000.0 in Q2 2024.

CDT Equity (CDT) Non-Current Debt (2023 - 2024) Analysis & Trends

CDT Equity (CDT) has 2 years of Non-Current Debt data on file, last reported at $200000.0 in Q3 2024.

Quarterly Non-Current Debt changed N/A year-over-year to $200000.0 in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $200000.0 (changed N/A YoY) and the FY2023 annual result came in at $200000.0, changed N/A from the prior year.
Non-Current Debt held at $200000.0 in Q3 2024, from $200000.0 in the prior quarter.
In the past five years, Non-Current Debt ranged from a high of $200000.0 in Q4 2023 to a low of $200000.0 in Q4 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	1.99 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	591.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	882.16 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	360.97 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	546.77 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	8.96 Bn
10	CDT Equity	1.55 Mn	1.55 Mn	-	1.14 Mn

Download Data